Newly diagnosed (within 6 months) people with Multiple Sclerosis (MS) sought for a trial comparing "first line" (traditional) with "second line" (aggressive) treatments in preventing disability. This is a pragmatic trial which means that even though participants will be randomly assigned a treatment group, they and their doctor can change their treatment if needed.
We will evaluate whether an “early aggressive/second line” therapy approach, versus starting with a traditional/ first-line therapy, prevents disability. We will also evaluate for MS patients who start on first-line therapies but experience breakthrough disease and switch therapies whether a new firstline/traditional therapy or a secondline/aggressive therapy better prevents disability.
What we're hoping for
We hope to evaluate whether treatment with traditional or aggressive therapy is better in preventing disability for newly diagnosed adults with Multiple Sclerosis (MS).
ClinicalTrials.gov Identifier: NCT03500328